BurstDR™ micrOdosing stimuLation in De-novo Patients (BOLD)
Primary Purpose
Pain, Intractable, Pain, Back
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.
Sponsored by
About this trial
This is an interventional treatment trial for Pain, Intractable
Eligibility Criteria
Inclusion Criteria:
- Subject is able to provide informed consent to participate in the study;
- Subject diagnosed with chronic intractable pain associated with back and/or limbs;
- Subject is 18 years of age or older;
- Subject has failed to respond to at least 6 months of conventional treatment which may include pharmacological treatment, physical therapy, epidural injections;
- Subject has a back and/or leg pain intensity of at least 6.0 cm out of 10.0 cm on the average back and/or leg pain visual analogue scale at baseline;
- Subject's medical record has been evaluated by the Investigator to ensure that the subject is a good candidate for a neurostimulation system;
- Subject is on stable pain medications with a total opioid for at least 28 days prior to enrolling in this study, and is willing to stay on those medications with no dose increase until the 3 month visit;
- Subject is willing to cooperate with the study requirements including compliance with the regimen and completion of all office visits;
- Female candidates of child-bearing potential agree to commit to the use of an effective method of contraception (including but not limited to sterilization, barrier devices, oral contraceptives, intrauterine devices (IUDs), condoms, rhythm method, or abstinence) for the duration of the study
Exclusion Criteria:
Subject has a current diagnosis of a coagulation disorder, bleeding diathesis, progressive peripheral vascular disease, post-herpetic neuralgia or uncontrolled diabetes mellitus;
- Subject is currently participating in a clinical investigation that includes an active treatment arm;
- Subject has been implanted with or participated in a trial period for a neurostimulation system;
- Subject has an infusion pump;
- Subject has evidence of an active disruptive psychological or psychiatric disorder as determined as per standard of care;
- Subject has a current diagnosis of a progressive neurological disease as determined by the Investigator;
- Subject is immunocompromised;
- Subject has an existing medical condition that is likely to require repetitive MRI evaluation in the future (i.e. epilepsy, stroke, multiple sclerosis, acoustic neuroma, tumor);
- Subject has history of cancer requiring active treatment in the last 12 months;
- Subject has an existing medical condition that is likely to require the use of diathermy in the future;
- Subject has documented history of allergic response to titanium or silicone;
- Subject has a documented history of substance abuse (narcotics, alcohol, etc.) or substance dependency in the 6 months prior to baseline data collection;
- Subject is a female candidates of child bearing potential that are pregnant (confirmed by positive urine/blood pregnancy test);
- Subject has life expectancy of less than 6 months;
- Subject is involved in an injury claim under current litigation
Sites / Locations
- Thrive Clinic
- Nevada advanced pain specialists
- OnSite Clinical Solutions
- Ambulatory Surgery Center of Killeen
- Premier Pain Solutions
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Microdosing group
Arm Description
Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.
Outcomes
Primary Outcome Measures
Change in Visual Analog Scale Pain (VAS) Scores Between Baseline and Trial Stimulation
Pain questionnaire - (Scale is 0-100 mm with 0 meaning no pain and 100 meaning worst pain imaginable)
Change in Visual Analog Scale Pain Scores Between Baseline and Follow up 1
Pain questionnaire - (Scale is 0-100 mm with 0 meaning no pain and 100 meaning worst pain imaginable)
Change in Visual Analog Scale Pain Scores Between Baseline and Follow up 2
Pain questionnaire - (Scale is 0-100 mm with 0 meaning no pain and 100 meaning worst pain imaginable)
Change in Visual Analog Scale Pain Scores Between Baseline and Follow up 3
Pain questionnaire - (Scale is 0-100 mm with 0 meaning no pain and 100 meaning worst pain imaginable)
Secondary Outcome Measures
Change in Quality of Life Between Baseline and Trial Stimulation
Questionnaire on quality of life using european quality of life - 5 dimension questionnaire (EQ-5D) - (Scale is between 0 and 1 with 0 being worse quality of life and 1 best quality of life)
Change in Quality of Life Between Baseline and Follow up 1
Questionnaire on quality of life using european quality of life - 5 dimension questionnaire (EQ-5D) - (Scale is between 0 and 1 with 0 being worse quality of life and 1 best quality of life)
Change in Quality of Life Between Baseline and Follow up 2
Questionnaire on quality of life using european quality of life - 5 dimension questionnaire (EQ-5D) - (Scale is between 0 and 1 with 0 being worse quality of life and 1 best quality of life)
Change in Quality of Life Between Baseline and Follow up 3
Questionnaire on quality of life using european quality of life - 5 dimension questionnaire (EQ-5D) - (Scale is between 0 and 1 with 0 being worse quality of life and 1 best quality of life)
Change in Disability Index Between Baseline and Trial Stimulation
questionnaire on disability, Oswestry Disability Index (ODI) - (Scale is between 0 and 100 with 0 being no disability and 100 worst disability)
Change in Disability Index Between Baseline and and Follow up 1
questionnaire on disability, Oswestry Disability Index (ODI) - (Scale is between 0 and 100 with 0 being no disability and 100 worst disability)
Change in Disability Index Between Baseline and and Follow up 2
questionnaire on disability, Oswestry Disability Index (ODI) - (Scale is between 0 and 100 with 0 being no disability and 100 worst disability)
Change in Disability Index Between Baseline and and Follow up 3
questionnaire on disability (ODI) - (Scale is between 0 and 100 with 0 being no disability and 100 worst disability)
Change in Pain Catastrophizing Scale Between Baseline and Trial Stimulation
Questionnaire on pain catastrophizing, Pain Catastrophising Scale (PCS) - (Scale is between 0 and 52 with 0 being no catastrophising and 52 worst catastrophising)
Change in Pain Catastrophizing Scale Between Baseline and Follow up 1
Questionnaire on pain catastrophizing, Pain Catastrophising Scale (PCS) - (Scale is between 0 and 52 with 0 being no catastrophising and 52 worst catastrophising)
Change in Pain Catastrophizing Scale Between Baseline and Follow up 2
Questionnaire on pain catastrophizing (PCS) - (Scale is between 0 and 52 with 0 being no catastrophising and 52 worst catastrophising)
Change in Pain Catastrophizing Scale Between Baseline and Follow up 3
Questionnaire on pain catastrophizing, Pain Catastrophising Scale (PCS) - (Scale is between 0 and 52 with 0 being no catastrophising and 52 worst catastrophising)
Full Information
NCT ID
NCT03350256
First Posted
November 10, 2017
Last Updated
March 6, 2020
Sponsor
Abbott Medical Devices
1. Study Identification
Unique Protocol Identification Number
NCT03350256
Brief Title
BurstDR™ micrOdosing stimuLation in De-novo Patients
Acronym
BOLD
Official Title
BurstDR™ micrOdosing stimuLation in De-novo Patients
Study Type
Interventional
2. Study Status
Record Verification Date
March 2020
Overall Recruitment Status
Completed
Study Start Date
October 30, 2017 (Actual)
Primary Completion Date
July 2, 2019 (Actual)
Study Completion Date
July 2, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Abbott Medical Devices
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate the therapeutic efficacy of microdosing BurstDR stimulation in spinal cord stimulation (SCS) patients with chronic intractable back and/or leg pain.
Detailed Description
Microdosing BurstDR consists of periods during which stimulation is delivered with standard BurstDR stimulation parameters alternated with periods during which no stimulation is being delivered.
In this study the investigators propose to evaluate therapeutic efficacy of BurstDR microdosing, and determine optimal microdosing programming parameters in chronic pain patients, who are eligible for SCS therapy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Intractable, Pain, Back
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
60 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Microdosing group
Arm Type
Experimental
Arm Description
Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.
Intervention Type
Device
Intervention Name(s)
Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.
Intervention Description
BurstDR spinal cord stimulation will be delivered with different ON/OFF periods to identify the best setting for each patients.
Primary Outcome Measure Information:
Title
Change in Visual Analog Scale Pain (VAS) Scores Between Baseline and Trial Stimulation
Description
Pain questionnaire - (Scale is 0-100 mm with 0 meaning no pain and 100 meaning worst pain imaginable)
Time Frame
baseline and 1 week after trial lead implant (trial stimulation)
Title
Change in Visual Analog Scale Pain Scores Between Baseline and Follow up 1
Description
Pain questionnaire - (Scale is 0-100 mm with 0 meaning no pain and 100 meaning worst pain imaginable)
Time Frame
Baseline and 1 month follow up visit
Title
Change in Visual Analog Scale Pain Scores Between Baseline and Follow up 2
Description
Pain questionnaire - (Scale is 0-100 mm with 0 meaning no pain and 100 meaning worst pain imaginable)
Time Frame
Baseline and 3 month follow up visit
Title
Change in Visual Analog Scale Pain Scores Between Baseline and Follow up 3
Description
Pain questionnaire - (Scale is 0-100 mm with 0 meaning no pain and 100 meaning worst pain imaginable)
Time Frame
Baseline and 6 month follow up visit
Secondary Outcome Measure Information:
Title
Change in Quality of Life Between Baseline and Trial Stimulation
Description
Questionnaire on quality of life using european quality of life - 5 dimension questionnaire (EQ-5D) - (Scale is between 0 and 1 with 0 being worse quality of life and 1 best quality of life)
Time Frame
Baseline and 1 week after trial lead implant (trial stimulation)
Title
Change in Quality of Life Between Baseline and Follow up 1
Description
Questionnaire on quality of life using european quality of life - 5 dimension questionnaire (EQ-5D) - (Scale is between 0 and 1 with 0 being worse quality of life and 1 best quality of life)
Time Frame
Baseline and 1 month follow up visit
Title
Change in Quality of Life Between Baseline and Follow up 2
Description
Questionnaire on quality of life using european quality of life - 5 dimension questionnaire (EQ-5D) - (Scale is between 0 and 1 with 0 being worse quality of life and 1 best quality of life)
Time Frame
Baseline and 3 month follow up visit
Title
Change in Quality of Life Between Baseline and Follow up 3
Description
Questionnaire on quality of life using european quality of life - 5 dimension questionnaire (EQ-5D) - (Scale is between 0 and 1 with 0 being worse quality of life and 1 best quality of life)
Time Frame
Baseline and 6 month follow up visit
Title
Change in Disability Index Between Baseline and Trial Stimulation
Description
questionnaire on disability, Oswestry Disability Index (ODI) - (Scale is between 0 and 100 with 0 being no disability and 100 worst disability)
Time Frame
Baseline and 1 week after trial lead implant (trial stimulation)
Title
Change in Disability Index Between Baseline and and Follow up 1
Description
questionnaire on disability, Oswestry Disability Index (ODI) - (Scale is between 0 and 100 with 0 being no disability and 100 worst disability)
Time Frame
Baseline and 1 month follow up visit
Title
Change in Disability Index Between Baseline and and Follow up 2
Description
questionnaire on disability, Oswestry Disability Index (ODI) - (Scale is between 0 and 100 with 0 being no disability and 100 worst disability)
Time Frame
Baseline and 3 month follow up visit
Title
Change in Disability Index Between Baseline and and Follow up 3
Description
questionnaire on disability (ODI) - (Scale is between 0 and 100 with 0 being no disability and 100 worst disability)
Time Frame
Baseline and 6 month follow up visit
Title
Change in Pain Catastrophizing Scale Between Baseline and Trial Stimulation
Description
Questionnaire on pain catastrophizing, Pain Catastrophising Scale (PCS) - (Scale is between 0 and 52 with 0 being no catastrophising and 52 worst catastrophising)
Time Frame
Baseline and 1 week after trial lead implant (trial stimulation)
Title
Change in Pain Catastrophizing Scale Between Baseline and Follow up 1
Description
Questionnaire on pain catastrophizing, Pain Catastrophising Scale (PCS) - (Scale is between 0 and 52 with 0 being no catastrophising and 52 worst catastrophising)
Time Frame
Baseline and 1 month follow up visit
Title
Change in Pain Catastrophizing Scale Between Baseline and Follow up 2
Description
Questionnaire on pain catastrophizing (PCS) - (Scale is between 0 and 52 with 0 being no catastrophising and 52 worst catastrophising)
Time Frame
Baseline and 3 month follow up visit
Title
Change in Pain Catastrophizing Scale Between Baseline and Follow up 3
Description
Questionnaire on pain catastrophizing, Pain Catastrophising Scale (PCS) - (Scale is between 0 and 52 with 0 being no catastrophising and 52 worst catastrophising)
Time Frame
Baseline and 6 month follow up visit
Other Pre-specified Outcome Measures:
Title
Stimulation ON/OFF Ratio
Description
Percentage of patients using each ON/OFF ratio
Time Frame
6 month follow up visit
10. Eligibility
Sex
All
Minimum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subject is able to provide informed consent to participate in the study;
Subject diagnosed with chronic intractable pain associated with back and/or limbs;
Subject is 18 years of age or older;
Subject has failed to respond to at least 6 months of conventional treatment which may include pharmacological treatment, physical therapy, epidural injections;
Subject has a back and/or leg pain intensity of at least 6.0 cm out of 10.0 cm on the average back and/or leg pain visual analogue scale at baseline;
Subject's medical record has been evaluated by the Investigator to ensure that the subject is a good candidate for a neurostimulation system;
Subject is on stable pain medications with a total opioid for at least 28 days prior to enrolling in this study, and is willing to stay on those medications with no dose increase until the 3 month visit;
Subject is willing to cooperate with the study requirements including compliance with the regimen and completion of all office visits;
Female candidates of child-bearing potential agree to commit to the use of an effective method of contraception (including but not limited to sterilization, barrier devices, oral contraceptives, intrauterine devices (IUDs), condoms, rhythm method, or abstinence) for the duration of the study
Exclusion Criteria:
Subject has a current diagnosis of a coagulation disorder, bleeding diathesis, progressive peripheral vascular disease, post-herpetic neuralgia or uncontrolled diabetes mellitus;
Subject is currently participating in a clinical investigation that includes an active treatment arm;
Subject has been implanted with or participated in a trial period for a neurostimulation system;
Subject has an infusion pump;
Subject has evidence of an active disruptive psychological or psychiatric disorder as determined as per standard of care;
Subject has a current diagnosis of a progressive neurological disease as determined by the Investigator;
Subject is immunocompromised;
Subject has an existing medical condition that is likely to require repetitive MRI evaluation in the future (i.e. epilepsy, stroke, multiple sclerosis, acoustic neuroma, tumor);
Subject has history of cancer requiring active treatment in the last 12 months;
Subject has an existing medical condition that is likely to require the use of diathermy in the future;
Subject has documented history of allergic response to titanium or silicone;
Subject has a documented history of substance abuse (narcotics, alcohol, etc.) or substance dependency in the 6 months prior to baseline data collection;
Subject is a female candidates of child bearing potential that are pregnant (confirmed by positive urine/blood pregnancy test);
Subject has life expectancy of less than 6 months;
Subject is involved in an injury claim under current litigation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Timothy R Deer, MD
Organizational Affiliation
The Center for Pain Relief
Official's Role
Principal Investigator
Facility Information:
Facility Name
Thrive Clinic
City
Santa Rosa
State/Province
California
ZIP/Postal Code
95403
Country
United States
Facility Name
Nevada advanced pain specialists
City
Reno
State/Province
Nevada
ZIP/Postal Code
89511
Country
United States
Facility Name
OnSite Clinical Solutions
City
Asheville
State/Province
North Carolina
ZIP/Postal Code
28803
Country
United States
Facility Name
Ambulatory Surgery Center of Killeen
City
Killeen
State/Province
Texas
ZIP/Postal Code
76542
Country
United States
Facility Name
Premier Pain Solutions
City
Charleston
State/Province
West Virginia
ZIP/Postal Code
25301
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
BurstDR™ micrOdosing stimuLation in De-novo Patients
We'll reach out to this number within 24 hrs